Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: KEGG:D02003 (
NBT
)
1,323
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
A mouse IgG1 monoclonal antibody ED12F8C10 (
C10
) binds a constant percentage of peripheral blood neutrophils in the same individual when studied over time, defining a distinct subset of neutrophils in all normal individuals studied to date. Bone marrow studies confirm that the heterogeneity is present to the same degree at all stages of neutrophil development from the myelocyte to the mature neutrophil. Neither in vivo nor in vitro activation of neutrophils explains or significantly alters the relative percentages of
C10
-positive and -negative neutrophils in the same individual. With both activation and exudation, however, expression of the
C10
-defined epitope increases in intensity in the
C10
binding subpopulation. Studies of
NBT
reduction, phagocytosis, adherence, light scattering characteristics, and monoclonal antibody surface binding have failed to demonstrate physical or functional differences between the
C10
-defined populations. We examined
C10
binding in patients with different defects of phagocyte function. In two patients with neutrophil-specific granule deficiency, less than 1% of the neutrophils were found to be
C10
positive, while neutrophils from a patient with idiopathic leukemoid reaction and recurrent infections demonstrated greater than 99%
C10
binding. Although the present study does not delineate the physiologic significance of
C10
binding heterogeneity, it firmly supports the concept of neutrophil heterogeneity at the level of surface antigen expression.
...
PMID:Unique human neutrophil populations are defined by monoclonal antibody ED12F8C10. 182 50